In a significant pre-IPO development, Gujarat-based healthcare provider Gujarat Kidney and Super Speciality has successfully mobilized substantial funds from institutional investors. The company announced on Friday that it has secured over ₹100 crore from a group of anchor investors, setting a positive tone for its upcoming public offering.
Anchor Investment Details and Marquee Participants
The company allocated a total of 87,73,120 equity shares to anchor investors at a price of ₹114 per share. This anchor book round saw participation from several prominent domestic and international funds, indicating strong institutional confidence. Key investors included Venus Investments VCC – Venus Stellar Fund, Khandelwal Finance Private Limited, and Craft Emerging Market Fund PCC Citadel Capital Fund.
Other notable institutions that subscribed to the anchor portion were Nexus Global Opportunities Fund, Arnesta Global Opportunities Fund PCC – Arnesta Global Fund 1, Zeta Global Funds – Zeta Series C Fund PC, Innovative Vision Fund, Religo Commodities Ventures Trust, and Sunrise Investment Trust.
IPO Structure and Key Dates for Investors
The Gujarat Kidney and Super Speciality IPO comprises a fresh issue of up to 2.20 crore equity shares. At the upper price band of ₹114, the total issue size aggregates to ₹250.8 crore. The subscription window for the public offering is set to open on Monday, December 22, 2025, and will close on Wednesday, December 24, 2025.
For retail and other investors, the minimum application lot is 128 equity shares, with bids to be placed in multiples thereof. The issue is being made through the book-building process, with the following reservation pattern:
- Up to 75% for Qualified Institutional Buyers (QIBs)
- Up to 15% for Non-Institutional Investors (NIIs)
- Up to 10% for Retail Individual Investors (RIIs)
Nirbhay Capital Services Private Limited is the book-running lead manager for this IPO, while MUFG Intime India Limited has been appointed as the registrar to the issue.
Company Profile and Grey Market Premium (GMP)
Gujarat Kidney and Super Speciality operates as a regional healthcare provider in central Gujarat, running a network of mid-sized multi-speciality hospitals. Its service model focuses on integrated healthcare with a strong emphasis on both secondary and tertiary care.
The company's secondary services encompass various surgical procedures, while its tertiary services include super-speciality surgical treatments. To provide a complete patient experience, the hospitals also offer integrated diagnostic facilities—some in-house and some through partners—along with pharmacy services.
In the unofficial market, shares of the company are commanding a premium ahead of the listing. According to data from Investorgain, the Grey Market Premium (GMP) for the Gujarat Kidney and Super Speciality IPO is ₹7. This translates to an estimated listing price of around ₹121, which would be approximately 6.14% higher than the IPO price of ₹114.
Disclaimer: This news article is for informational and educational purposes only. The views and recommendations mentioned are those of individual analysts or broking firms. Readers are strongly advised to consult with SEBI-certified investment experts before making any financial decisions.
